NCT03463460 2025-08-24
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
Clinical Trials
24 trialsNCT01306045 2024-10-01
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01621568 2024-09-24
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00698815 2022-02-08
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00695292 2021-11-22
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03449173 2021-06-09
Style
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02623127 2019-01-23
KOSMIC
Seoul National University Hospital
Phase 2 Completed
NCT01829217 2018-10-31
Sunitinib in Never-Smokers With Lung Adenocarcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00864721 2018-10-16
Sunitinib Non Small Cell Lung Cancer Patients Over 70
US Oncology Research
Phase 2 Completed
NCT00748163 2018-08-08
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT00953459 2018-07-26
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01803503 2016-06-22
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
National University Hospital, Singapore
Phase 2 Unknown
NCT00392444 2014-05-21
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00616109 2014-04-21
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00620347 2013-06-19
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT01850147 2013-05-09
Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen
ChineseAMS
Phase 2 Unknown
NCT00265317 2013-02-06
SUN1058
Pfizer
Phase 2 Completed
NCT00372775 2011-02-24
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
Pfizer
Phase 2 Completed
NCT00430261 2010-10-06
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Swedish Medical Center
Phase 2 Completed
NCT01210053 2010-09-28
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Third Military Medical University
Phase 2 Unknown
NCT00113516 2010-05-18
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT01019798 2009-11-25
Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
Taipei Medical University Hospital
Phase 2 Unknown
NCT00434226 2009-08-21
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
Genentech, Inc.
Phase 2 Terminated
NCT00092001 2008-10-16
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed